These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20347059)

  • 1. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inactivated cell-culture vaccine against yellow fever.
    Monath TP; Fowler E; Johnson CT; Balser J; Morin MJ; Sisti M; Trent DW
    N Engl J Med; 2011 Apr; 364(14):1326-33. PubMed ID: 21470010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.
    Julander JG; Trent DW; Monath TP
    Vaccine; 2011 Aug; 29(35):6008-16. PubMed ID: 21718741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
    Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
    Vaccine; 2015 Aug; 33(35):4261-8. PubMed ID: 25862300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
    Pfister M; Kürsteiner O; Hilfiker H; Favre D; Durrer P; Ennaji A; L'Age-Stehr J; Kaufhold A; Herzog C
    Am J Trop Med Hyg; 2005 Mar; 72(3):339-46. PubMed ID: 15772332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
    Amanna IJ; Thomas A; Engelmann F; Hammarlund E; Raué HP; Bailey AL; Poore EA; Quintel BK; Lewis AD; Axthelm MK; Johnson AL; Colgin LMA; Diamond MS; Messaoudi I; Slifka MK
    Cell Rep Med; 2024 Jul; 5(7):101655. PubMed ID: 39019010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
    Freire MS; Mann GF; Marchevsky RS; Yamamura AM; Almeida LF; Jabor AV; Malachias JM; Coutinho ES; Galler R
    Vaccine; 2005 Mar; 23(19):2501-12. PubMed ID: 15752837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine.
    Lim CK; Takasaki T; Kotaki A; Kurane I
    Virology; 2008 Apr; 374(1):60-70. PubMed ID: 18221765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
    Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
    Mantel N; Piras-Douce F; Chautard E; Marcos-Lopez E; Bodinham CL; Cosma A; Courtois V; Dhooge N; Gautheron S; Kaufmann SHE; Pizzoferro K; Lewis DJM; Martinon F; Pagnon A; Raynal F; Dereuddre-Bosquet N; Le Grand R
    J Virol; 2024 May; 98(5):e0151623. PubMed ID: 38567951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
    Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it time for a new yellow fever vaccine?
    Hayes EB
    Vaccine; 2010 Nov; 28(51):8073-6. PubMed ID: 20971115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.